<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922363</url>
  </required_header>
  <id_info>
    <org_study_id>ACAF01-01</org_study_id>
    <nct_id>NCT00922363</nct_id>
  </id_info>
  <brief_title>Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers</brief_title>
  <official_title>An Open Phase I, Dose-escalating, Clinical Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Statens Serum Institut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile of CAF01, administering 50 µg
      Ag85B-ESAT-6 alone and 50 µg Ag85B-ESAT-6 with three escalating CAF01 dose levels, to four
      groups of healthy volunteers, injecting two doses with two months interval.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>one year after first vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>one year after the first vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>50 µg Ag85B-ESAT-6 alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50 µg Ag85B-ESAT-6 + 125/25 µg CAF01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50 µg Ag85B-ESAT-6 + 313/63 µg CAF01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50 µg Ag85B-ESAT-6 + 625/125 µg CAF01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 µg Ag85B-ESAT-6 alone</intervention_name>
    <description>0.5 mL solution for injection x 2 (2 months interval)</description>
    <arm_group_label>50 µg Ag85B-ESAT-6 alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 µg Ag85B-ESAT-6 + 125/25 µg CAF01</intervention_name>
    <description>0,5 mL suspension for injection x 2 (2 months interval)</description>
    <arm_group_label>50 µg Ag85B-ESAT-6 + 125/25 µg CAF01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 µg Ag85B-ESAT-6 + 313/63 µg CAF01</intervention_name>
    <description>0.5 mL suspension for injection x 2 (2 months interval)</description>
    <arm_group_label>50 µg Ag85B-ESAT-6 + 313/63 µg CAF01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 µg Ag85B-ESAT-6 + 625/125 µg CAF01</intervention_name>
    <description>0.5 mL suspension for injection x 2 (2 months interval)</description>
    <arm_group_label>50 µg Ag85B-ESAT-6 + 625/125 µg CAF01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or male adult between 18 and 55 years of age

          2. Healthy according to medical history and medical examinations at screening

          3. Signed informed consent

          4. Prepared to grant authorized persons access to medical records

          5. Likely to comply with instructions

        Exclusion Criteria:

          1. History of tuberculosis or known exposure to tuberculosis before (or expected during)
             the clinical trial

          2. Positive Tuberculin Skin Test (TST) result at screening

          3. Positive QuantiFERON® -TB Gold In-Tube test result according to the manufacturer's
             specifications at screening

          4. BCG vaccination any time before entering the trial

          5. History of or ongoing congenital or acquired immune deficiency, autoimmune disease or
             thyroid dysfunction

          6. Disease affecting the lymphoid organs (Hodgkin's disease, lymphoma, leukaemia,
             sarcoidosis)

          7. ANA-Titer, HBV, HCV, HIV sero-positive at screening

          8. C-reactive protein level &gt; 50 mg/L at screening

          9. Clinically significant abnormal laboratory test results at screening as assessed by
             the investigator

         10. Severe ongoing viral or bacterial infection that might affect the cell mediated immune
             response

         11. A condition in which repeated blood drawings pose more than minimal risk for the
             subject, such as haemophilia, other coagulation disorders, or significantly impaired
             venous access

         12. Live vaccine vaccination (MMR, yellow fever, oral typhoid) within 3 months before the
             first vaccination

         13. Immune modulating drugs administration (immunoglobulin, systemic corticosteroids,
             azathioprine, cyclosporine, infliximab, blood products or vaccines) within 3 months
             before the first vaccination

         14. Known hypersensitivity to any of the vaccine components of the investigational
             vaccines

         15. Intake of another clinical trial product/vaccine within 3 months before the first
             vaccination or participation in previous clinical trials with the Ag85B-ESAT-6 antigen

         16. Pregnant according to a urine pregnancy test at inclusion

         17. Females not willing to use contraceptives or breast feeding

         18. Has a condition which in the opinion of the investigator is not suitable for
             participation in the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of infectious diseases, C5-P, LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>NL-2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>vaccine</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>CAF01</keyword>
  <keyword>Ag85B-ESAT-6</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

